Source: Health Products Regulatory Authority (IE) Revision Year: 2019 Publisher: CIS bio International, Route Nationale 306 Saclay, BP 32, 91192 Gif-Sur-Yvette Cedex, France
Pharmacotherapeutic group: Diagnostic radiopharmaceuticals for the renal system Technetium (99mTc) compounds
ATC code: V09CA02
At the chemical concentrations used for diagnostic procedures technetium (99mTc) succimer does not appear to have any pharmacodynamic effects.
Technetium (99mTc) succimer is cleared from blood with a triphasic pattern in patients with normal renal function.
The technetium (99mTc) succimer localizes in high concentrations in renal cortex. Maximal localization occurs within 3-6 hours after intravenous injection, with about 40‑50 % of the dose retained in the kidneys. Less than 3 % of the administered dose localizes in the liver. However, this amount can be increased significantly and renal distribution decreased in patients with impaired renal functions.
Excretion is exclusively via the kidneys.
The effective half-life of technetium (99mTc) succimer in blood is around 1 hour.
Toxicity with repeated administration of 0.66 mg/kg/day succimer and 0.23 mg/kg/day SnCl2 over 14 days in rats was not observed. The dose usually administered to humans is 0.14 mg/kg succimer. This agent is not intended for regular or continuous administration.
Mutagenicity studies and long-term carcinogenicity studies have not been carried out.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
